BioGaia probiotic found to prevent recurrent diarrhea and promote growth in children

a56e4159-6c57-45b5-bc01-710f73a4865darticleimage.jpg

07 Nov 2017 --- Rapid diagnostic testing in combination with Lactobacillus reuteri Protectis supplementation for 60 days has been linked to a significant increase in height and significantly less recurrent diarrhea in study of 71 infants with acute diarrhea, as compared to standard care and placebo treatment. Lactobacillus reuteri Protectis is a strain developed by Swedish healthcare company BioGaia.

“These results are very exciting. Our trial has shown that the administration of L. reuteri DSM 17938 shows real promise to mitigate the devastating effects of diarrheal disease in sub-Saharan Africa,” says Associate Professor Jeffrey Pernica at McMaster Children’s Hospital in Hamilton, Canada, lead investigator of the study.

“Previous probiotic trials have focused on outcomes such as duration of diarrhea, which are somewhat relevant for families and clinicians, but not nearly as important as a hard outcome such as standardized height, which has been directly linked to stunting, cognitive deficiencies, and eventual adult accomplishment,” Pernica explains. “The combination of test-and-treat diagnostics and L. reuteri DSM 17938 was associated with 93 percent lower odds of recurrent diarrhea in the 60-day follow-up period, as well as a dramatic increase in age-standardized height.”

Diarrhea kills and disables children
Diarrhea is the second-leading cause of mortality in the world among children under the age of 5, as well as a major cause of both growth failure and impaired cognitive development. There is a clear need for improvements in diarrheal disease management in resource-limited settings.

The pilot study was conducted in Botswana and demonstrated that the use of molecular rapid enteric diagnostics (permitting timely targeted antimicrobial therapy) and the administration of L. reuteri Protectis were both feasible in a resource-limited sub-Saharan African context. These interventions led to significant increases in growth and decreases in recurrent diarrhea. The next step will be to validate these findings in a trial with a much larger number of children.

BioGaia first announced the results in October 2015 when the study was presented for the first time at The Infectious Disease Week in San Diego, USA, but the findings were published in PLOS ONE on 9 October.

“We had announced the results of this study already, in October 2015, but now have the opportunity to highlight them again. The fact that L. reuteri Protectis may mitigate terrible consequences of diarrheal disease, like stunting, cognitive deficiencies, and eventual adult accomplishments, and contribute to a decrease in recurrent diarrhea, increased growth and improved quality of life for children in sub-Saharan countries is very encouraging”, says Axel Sjöblad, Managing Director at BioGaia.

To contact our editorial team please email us at editorial@cnsmedia.com

Related Articles

Nutrition & Health News

Microbiome solutions: A key theme at Vitafoods Europe 2018

24 May 2018 --- Research into the microbiome – the aggregated microbial species in our body – is gaining increasing attention and investment. Although the term is often associated with digestive health, the body, in fact, contains multiple microbiome. This is currently spurring on research and innovation in areas as wide-ranging as women’s health, weight management, immunity and skin health. At Vitafoods Europe 2018, NutritionInsight spoke with suppliers about their efforts and innovations in the microbiome space, using pre or probiotics for gut health and beyond.

Nutrition & Health News

Key gut-brain interplays identified, enhancing possibilities for neurological treatments

21 May 2018 --- Steps have been taken toward untangling the complex interplay that allows the byproducts of microorganisms living in the gut to influence the progression of neurodegenerative diseases. Researchers have defined a pathway between the two, coined the gut-brain axis, that may help guide therapies for multiple sclerosis and other neurological diseases. Essentially, some gut microbes were found to activate an anti-inflammatory pathway that can limit neurodegeneration.

Nutrition & Health News

Sports nutrition mainstreams: A key theme at Vitafoods Europe 2018

18 May 2018 --- Boundaries are blurring as sports nutrition continues to move mainstream. Ingredients and products aimed at promoting active living were a clear standout theme at Vitafoods Europe this year. New launches targeted a wide scope of aspects related to active lifestyles, and are likely to resonate not just with hardcore athletes but also with consumers of different ages and activity groups. 

Nutrition & Health News

Protein provides benefit for adult bone and joint health, expert consensus reports

17 May 2018 --- Dietary protein intake above the recommended levels may help reduce bone loss and fracture risk in seniors with osteoporosis, an expert consensus reports. Based on an analysis of major research studies, the review, published in Osteoporosis International, found that a protein-rich diet is beneficial for adult bone health. The consensus debunks the popular myth that too much protein may be damaging to bone health.

Nutrition & Health News

“Key milestone”: Chr. Hansen trial finds probiotic potential for painkiller gut damage defense

16 May 2018 --- A Chr. Hansen clinical trial has demonstrated the effectiveness of probiotic strains in protecting against potential gut damage caused by the regular use of household painkillers. Chr. Hansen state that they will now focus on fully exploiting the strains full potential, deepening understanding of the underlying mechanisms and gathering sufficient data to publish in a scientific journal. The findings add to a growing research area using probiotics for health.

More Articles
URL : http://www.nutritioninsight.com:80/news/biogaias-probiotic-found-to-prevent-recurrent-diarrhea-and-promote-growth-in-children.html